Arbidol powder for suspension 25mg / 5ml, 37g

• Prevention and treatment of influenza A and B, other acute respiratory viral infections in children from 2 years of age and adults;

• complex therapy of acute intestinal infections of rotavirus etiology in children from 2 years of age;

• non-specific prevention of severe acute respiratory syndrome (SARS) in children from 6 years of age and adults; treatment of severe acute respiratory syndrome (SARS) in children over 12 years of age and adults.

The drug is taken orally, before meals.

Suspension preparation

In a bottle containing powder,

add 30 ml (or about 2/3 of the volume of the bottle) boiled water cooled to room temperature. Close the bottle with a lid, turn over and shake thoroughly until a homogeneous suspension is obtained. Add boiled and cooled water to a volume of 100 ml (up to the mark on the bottle) and shake again. Before each use, shake the contents of the bottle thoroughly until a homogeneous suspension is obtained.

Measure out a single dose using the supplied measuring spoon.

The reception regimen depends on the age

Powder for preparation of suspension for oral administration is granular, white or almost white in color, with a characteristic fruity odor; the prepared suspension is a uniform color, white or white with a yellowish or creamy shade, with a characteristic fruity odor.

5 ml ready-made suspension.

umifenovir hydrochloride monohydrate 25.88 mg,?

which corresponds to the content of umifenovir hydrochloride 25 mg

Excipients: sodium chloride - 26.85 mg, maltodextrin (Kleptose Linecaps) - 750 mg, sucrose (sugar) - 840.42 mg, colloidal silicon dioxide (Aerosil) - 24.6 mg, titanium dioxide - 25 mg, pregelatinized starch (type PA5PH) - 129.5 mg, sodium benzoate - 9.25 mg, banana flavor - 12.4 mg, cherry flavor - 6.1 mg.

• Hypersensitivity to umifenovir or any component of the drug;

• age up to 2 years; age up to 6 years (according to the indication, non-specific prophylaxis of SARS);

• age up to 12 years (according to indications for the treatment of SARS).

• deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption.

pharmachologic effect

Antiviral agent. Specifically suppresses in vitro influenza A and B viruses (Influenza virus A, B), including highly pathogenic subtypes A (H1N1) pdm09 and A (H5N1), as well as other viruses that cause ARVI (Coronavirus associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)). By the mechanism of antiviral action, it belongs to fusion inhibitors (fusion), interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has interferon-inducing activity - in a study on mice, the induction of interferons was noted already after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration.Stimulates cellular and humoral reactions of immunity: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells). Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with a viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effects on the human body when taken orally in recommended doses.increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells). Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with a viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells). Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with a viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells). Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with a viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.stimulates the phagocytic function of macrophages and increases the number of natural killer cells (NK cells). Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the incidence of complications associated with a viral infection and exacerbations of chronic bacterial diseases. Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effect on the human body when taken orally in recommended doses.Refers to low-toxic drugs (LD50> 4 g / kg). Does not have any negative effects on the human body when taken orally in recommended doses.

Pharmacokinetics

Absorption and distribution Rapidly absorbed and distributed to organs and tissues. Cmax in blood plasma when taking the drug at a dose of 200 mg of umifenovir is achieved after 1 hour, Vd - 1432 liters. Metabolism and excretion Metabolized in the liver. T1 / 2 averages 11 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and, in small amounts, by the kidneys (0.12%). During the first day, 90% of the administered dose is excreted.

Side effect

Allergic reactions: rarely (with a frequency of? 1/10 000, but <1/1000) - itching, rash, angioedema, urticaria; very rarely (with a frequency of <1/10 000) - anaphylactic reactions. If any of the side effects indicated in the instructions are aggravated, or the patient has noticed any other side effects not listed in the instructions, he should inform the doctor about it.

Application during pregnancy and lactation

The use of the drug ArbidolЃ during pregnancy is contraindicated. It is not known whether the active substance of the drug ArbidolЃ or its metabolites penetrates into breast milk in women during lactation. If it is necessary to use the drug ArbidolЃ, breastfeeding should be stopped.

Application in children

The use of the drug under the age of 2 years is contraindicated; under the age of 6 years (according to the indication, non-specific prophylaxis of SARS); under the age of 12 (according to the indication for the treatment of SARS).

special instructions

When prescribing to patients with diabetes mellitus, as well as with a low-calorie diet, it should be borne in mind that the suspension contains sucrose (0.8 g / 5 ml or 0.06 XE / 5 ml). It is necessary to observe the scheme and duration of the drug intake recommended in the instructions. In case of missing one dose of the drug, the missed dose should be taken as early as possible and the course of taking the drug should be continued according to the started scheme. When calculating the amount of suspension required for the course of administration, it is necessary to take into account the shelf life of the prepared suspension, which is 10 days. For a course of admission, as indicated, nonspecific prophylaxis during an epidemic of influenza and other acute respiratory viral infections in children from 2 to 6 years old will require 2 bottles of ArbidolЃ.

Influence on the ability to drive vehicles and mechanisms

It does not show central neurotropic activity and can be used in medical practice in people of various professions, incl. requiring increased attention and coordination of movements (transport drivers, operators, etc.).

Overdose

There were no cases of drug overdose.

Drug interactions

When administered with other drugs, no negative effects were noted.